Zev A. Wainberg, MD

Zev A. Wainberg, MD, MSc, is a professor of medicine in the Department of Medicine at UCLA and co-director of the UCLA GI Oncology Program

Articles

Dr Wainberg on Phase 2 Domvanalimab/Zimberelimab/Chemo Data in Gastric Cancer

June 30th 2025

Zev A. Wainberg, MD, MSc, discusses data from the EDGE-Gastric trial of domvanalimab plus zimberelimab and FOLFOX in first-line, metastatic gastric cancer.

Dr Wainberg on the Phase 2/3 ASPEN-06 Study of Evorpacept in HER2-Overexpressing Gastric/GEJ Cancer

January 26th 2025

Zev A. Wainberg, MD, discusses findings from the phase 2/3 ASPEN-06 trial (NCT05002127) of evorpacept plus trastuzumab, ramucirumab, and paclitaxel in HER2-overexpressing gastric/GEJ cancer.

FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer

March 11th 2024

Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma.

Dr Wainberg on the FDA Approval of NALIRIFOX in mPDAC

February 13th 2024

Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Wainberg on the Rationale for the Phase 3 NAPOLI 3 Trial in Patients With PDAC

March 9th 2023

Zev A. Wainberg, MD, discusses the rationale behind the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Wainberg on Liposomal Irinotecan/NALIRIFOX vs Nab-paclitaxel/Gemcitabine in PDAC

January 22nd 2023

Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Dr. Wainberg on Optimal Frontline Treatment Strategies for Metastatic ESCC

January 17th 2023

Zev A. Wainberg, MD, discusses standard frontline treatment approaches for patients with metastatic esophageal squamous cell carcinoma and highlights data supporting the use of tislelizumab in combination with chemotherapy in ESCC.

Dr. Wainberg on the Need for Continued Enrollment to Clinical Trials in CRC

September 20th 2021

Zev A. Wainberg, MD, discusses the importance of enrolling patients with colorectal cancer to clinical trials, despite the difficulties caused by COVID-19.

KRAS G12C Inhibitors in mCRC

June 22nd 2021

A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.

Future Directions in mCRC

June 22nd 2021

Drs Jaffer A. Ajani and Zev A. Wainberg comment on current obstacles surrounding the treatment of metastatic colorectal cancer and consider the future use of ctDNA as more is learned about the disease.

EGFR Therapy for mCRC: Dermatologic Toxicity

June 15th 2021

Best practices for managing skin rashes associated with anti-EGFR therapy for metastatic colorectal cancer.

Later-Line Treatment Options for mCRC

June 15th 2021

Recommendations for treating patients with relapsed/refractory metastatic colorectal cancer in the third-line or later settings with regorafenib or TAS-102 therapy.

Sequencing Anti-EGFR Therapy in mCRC

June 8th 2021

The importance of aligning second-line treatment decisions with patient goals in metastatic colorectal cancer, and the benefits of treating patients with biweekly cetuximab, especially during the COVID-19 pandemic.

Changes in Cetuximab Dosing Schedule in mCRC

June 8th 2021

Reactions to recent changes approved by the FDA to the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Selecting Systemic Therapy for Newly Diagnosed mCRC

June 1st 2021

Treatment approaches available for patients with newly diagnosed metastatic colorectal cancer that is RAS wild type and factors that impact decisions for utilizing a 2-drug versus 3-drug regimen.

Next-Generation Sequencing in Metastatic Colorectal Cancer

June 1st 2021

Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.

Molecular Testing in Metastatic Colorectal Cancer

May 25th 2021

The significance of studying genomics in metastatic colorectal cancer and an overview of actionable targets that can be tested for to help in treatment decisions for newly diagnosed disease.

Trends in Colorectal Cancer Incidence

May 25th 2021

Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.

Dr. Wainberg on Optimal Dosing With Regorafenib in CRC

April 19th 2021

Zev A. Wainberg, MD, discusses optimal dosing with regorafenib in colorectal cancer.

Dr. Wainberg on the Potential Role of Neoadjuvant Chemotherapy in Pancreatic Cancer

April 1st 2021

Zev A. Wainberg, MD, discusses the potential role of neoadjuvant chemotherapy in pancreatic cancer.